Accelerating gene therapy projects from DNA design to commercial scale

We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions.

Our offering

Meet our team

DINAMIQS at a glance

Download the brochure

Highly skilled team with 80+ years combined experience

Demonstrated track record of achievement in viral vector manufacturing
Experienced with multiple AAV serotypes and scales
Focus on innovation
Deep understanding of regulatory requirements

End-to-end solutions from R&D to commercial manufacturing

Scalable platform including analytical solutions
GMP-compatible processes from early phase, reducing efforts, time and costs in transition from R&D to GMP
Upstream and downstream process development capabilities
Preclinical AAV vector manufacturing from 0.5-liter to 50-liter scale
cGMP scale production up to 1000-liter

Customer-centric partner tailored to meet your needs

Integrated, efficient, and time-saving pathways
Close collaboration with effective communication
Continuous development support and assistance

Member of the Siegfried network, a globally leading CDMO

Full access to Siegfried’s sterile drug products manufacturing network in US and Europe
Full support to transform from a start-up to a best-in-class CDMO

Visit the Siegfried website.

Tackling challenges in viral vector manufacturing

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS works to overcome these challenges.